Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $46.45 USD
Change Today -0.33 / -0.71%
Volume 483.0K
JUNO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

juno therapeutics inc (JUNO) Snapshot

Open
$46.88
Previous Close
$46.78
Day High
$47.15
Day Low
$46.16
52 Week High
04/15/15 - $66.00
52 Week Low
12/19/14 - $34.71
Market Cap
4.2B
Average Volume 10 Days
1.2M
EPS TTM
--
Shares Outstanding
90.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JUNO THERAPEUTICS INC (JUNO)

juno therapeutics inc (JUNO) Related Businessweek News

No Related Businessweek News Found

juno therapeutics inc (JUNO) Details

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The company’s additional product candidates comprise CD22, a cell surface protein expressed on B lymphocytes; CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein that is in Phase I/II clinical trials to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. Juno Therapeutics, Inc. has collaboration agreements with Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children’s Research Institute. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.

127 Employees
Last Reported Date: 05/12/15
Founded in 2013

juno therapeutics inc (JUNO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $671.0K
Chief Financial Officer and Head of Corporate...
Total Annual Compensation: $383.5K
Executive Vice President of Research & Develo...
Total Annual Compensation: $566.7K
Compensation as of Fiscal Year 2014.

juno therapeutics inc (JUNO) Key Developments

Juno Therapeutics, Inc. Announces Research Collaboration and License Agreement with Fate Therapeutics, Inc

Juno Therapeutics, Inc. and Fate Therapeutics, Inc. announced a strategic research collaboration and license agreement to identify and utilize small molecules to enhance therapeutic potential of Juno's genetically-engineered T cell product candidates for cancer patients. The collaboration brings together Juno's expertise in the development of chimeric antigen receptor (CAR) and T cell receptor (TCR) based cellular immunotherapies and Fate's innovative platform for programming the biological properties and in vivo therapeutic potential of hematopoietic cells. Through the four-year R&D collaboration, Fate will be responsible for screening and identifying small molecules that modulate the biological properties of engineered T cells. Juno will be responsible for the development and commercialization of engineered T cell immunotherapies incorporating Fate's small molecule modulators. Juno has the option to extend the exclusive research term for two years through an additional payment and continued funding of collaboration activities. Financial terms of the agreement include an upfront payment to Fate of $5 million and the purchase by Juno of one million shares of Fate common stock at $8.00 per share. Juno will fund all mutual collaboration activities for an exclusive four-year research term. For each product developed by Juno that incorporates modulators identified through the collaboration, Fate is eligible to receive approximately $50 million in target selection fees and clinical, regulatory and commercial milestones, as well as low single-digit royalties on sales. Fate retains exclusive rights to its intellectual property for all purposes outside of programmed CAR and TCR immunotherapies.

Juno Therapeutics Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Provides Cash Burn Guidance for 2015

Juno Therapeutics Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $65,160,000 compared to $8,320,000 a year ago. Net loss was $64,965,000 compared to $8,949,000 a year ago. Net loss per basic and diluted share was $0.97 compared to $1.41 a year ago. Non-GAAP net loss was $24,159,000 of $0.30 per basic and diluted share. Cash burn was $26.4 million compared to $13.3 million in the first quarter of 2014. The increase of $13.1 million was primarily due to increased cash used in operations of $12.1 million related to the overall growth of Juno’s business, including the hiring of key talent, increased purchases of property and equipment of $2.1 million, and the payment of costs related to Juno’s IPO of $1.7 million. The company expects to burn between $125 million and $150 million in cash in 2015, excluding cash inflows or outflows from business development activities and the now-settled litigation.

Juno Therapeutics Inc. and Fate Therapeutics, Inc. Announces Execution of Strategic Research Collaboration and License Agreement

Juno Therapeutics Inc. and Fate Therapeutics Inc. announced that they have executed a strategic research collaboration and license agreement to identify and utilize small molecules to modulate Juno's genetically-engineered T cell product candidates to improve their therapeutic potential for cancer patients. The collaboration brings together Juno's expertise in the development of chimeric antigen receptor (CAR) and T cell receptor (TCR) based cellular immunotherapies and Fate's innovative platform for programming the biological properties and in vivo therapeutic potential of hematopoietic cells. Through the four-year research and development collaboration, Fate will be responsible for screening and identifying small molecules that modulate the biological properties of engineered T cells. Juno will be responsible for the development and commercialization of engineered T cell immunotherapies incorporating Fate's small molecule modulators. Juno has the option to extend the exclusive research term for two years through an additional payment and continued funding of collaboration activities. Financial terms of the agreement include an upfront payment to Fate of $5 million and the purchase by Juno of one million shares of Fate common stock at $8.00 per share. Juno will fund all mutual collaboration activities for an exclusive four-year research term. For each product developed by Juno that incorporates modulators identified through the collaboration, Fate is eligible to receive approximately $50 million in target selection fees and clinical, regulatory and commercial milestones, as well as low single-digit royalties on sales. Fate retains exclusive rights to its intellectual property for all purposes outside of programmed CAR and TCR immunotherapies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUNO:US $46.45 USD -0.33

JUNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JUNO.
View Industry Companies
 

Industry Analysis

JUNO

Industry Average

Valuation JUNO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JUNO THERAPEUTICS INC, please visit www.junotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.